LL-37
LL-37 is a naturally occurring peptide that forms part of the body’s first line of defense. Researchers study its antimicrobial activity, immune signaling, inflammation, skin protection, tissue repair, and role in the wound-healing process.
LL-37 AT A GLANCE
WHAT IS LL-37?
LL-37 is a peptide made from 37 amino acids. Its name comes from the two leucine amino acids at its beginning and its total length. It is the active portion of a larger protein called hCAP18 and is the only known human member of the cathelicidin family of antimicrobial peptides.
LL-37 is produced by several types of immune and surface-lining cells, including neutrophils, macrophages, skin cells, and cells lining the airways and digestive system. Its presence in these tissues allows it to participate in the body’s early response to injury and possible microbial threats.
HOW DOES LL-37 WORK?
LL-37 has a positive electrical charge that attracts it to the negatively charged membranes of many microorganisms. It can interact with these membranes and disturb their structure, contributing to antimicrobial activity against certain bacteria, fungi, and viruses in laboratory studies. Its effectiveness can vary significantly depending on concentration, surrounding salts, proteins, and the organism involved.
The peptide also communicates with human cells through several receptors and signaling pathways. It can recruit immune cells, influence cytokine production, encourage new blood-vessel formation, and support the movement of skin cells during tissue repair. These varied actions mean LL-37 may either limit or promote inflammation depending on the biological setting.
Areas of Research
LL-37 research extends beyond its direct antimicrobial activity because the peptide also influences immune coordination, inflammation, and cellular responses to tissue damage.
ANTIMICROBIAL DEFENSE
Examining activity involving bacteria, fungi, enveloped viruses, microbial membranes, and the formation or disruption of biofilms.
IMMUNE SIGNALING
Studying how LL-37 recruits immune cells and influences cytokines, receptors, and communication between innate and adaptive immune responses.
WOUND HEALING AND SKIN REPAIR
Exploring skin-cell migration, new blood-vessel formation, wound closure, and protection of damaged tissue from microbial activity.
INFLAMMATORY CONDITIONS
Investigating how insufficient, excessive, or misplaced LL-37 activity may contribute to conditions involving the skin, lungs, joints, and autoimmune system.
Research Highlights
Laboratory research has established that LL-37 can interact with microbial membranes while also influencing immune activity and tissue repair. Animal studies have reported improved wound closure, and small human trials have examined topical LL-37 for difficult-to-heal venous leg ulcers and mildly infected diabetic foot ulcers. However, LL-37 can also contribute to unwanted inflammation and autoimmune activity, particularly in conditions such as psoriasis. These complex effects prevent early findings from establishing LL-37 as a broadly safe or effective treatment for infections, immune conditions, or wound healing.
WHAT IS LL-37 MOST COMMONLY RESEARCHED FOR?
LL-37 is most commonly studied for antimicrobial defense and immune regulation. Researchers examine how it responds to microorganisms, influences inflammatory signals, recruits immune cells, and helps protect tissues exposed to the outside environment. Its involvement in skin repair has also made wound healing an important area of investigation.
HOW DOES LL-37 FIT INTO PEPTIDE RESEARCH?
LL-37 is an example of a host-defense peptide, a group of naturally produced molecules that help protect the body while coordinating immune responses. Unlike peptides designed to stimulate one specific hormone pathway, LL-37 can interact with microbial membranes and several human signaling systems. This gives it a wide range of effects but also makes its activity difficult to predict.
WHAT MAKES LL-37 UNIQUE?
LL-37 combines direct antimicrobial activity with broader effects on inflammation, immune-cell movement, blood-vessel formation, and tissue repair. It can also bind microbial molecules such as lipopolysaccharide and interact with DNA or RNA released from damaged cells. Depending on the setting, these actions may help control a threat or contribute to excessive immune activation.
CAN LL-37 BE RESEARCHED ALONGSIDE OTHER PEPTIDES?
Researchers may compare LL-37 with Thymosin Alpha-1, KPV, BPC-157, or other compounds studied in connection with immune and tissue responses. These peptides work through different pathways, and there is limited controlled evidence establishing how experimental combinations behave. Findings involving one compound should not be used to predict the effects of another or of a combination.
WHAT HAVE RESEARCHERS LEARNED ABOUT LL-37 SO FAR?
Researchers have learned that LL-37 plays a complicated role in human defense. Appropriate activity may help control microorganisms, direct immune cells, and support tissue repair. Too little activity may weaken local defenses, while excessive or incorrectly regulated activity has been connected with inflammatory and autoimmune conditions. Cancer research has also produced conflicting findings, with LL-37 associated with either tumor-promoting or tumor-limiting activity depending on the cancer type and experimental conditions.
IS RESEARCH ON LL-37 CONTINUING TODAY?
Yes. LL-37 remains an active subject of research involving antimicrobial resistance, biofilms, chronic wounds, inflammatory skin conditions, respiratory health, autoimmune activity, and cancer biology. Researchers are also developing shorter fragments, modified analogs, and targeted delivery systems intended to preserve useful activity while reducing instability and unwanted inflammatory effects.